Synergy Pharmaceuticals Reports Second Quarter 2013 Financial Results

Published: Aug 09, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results and business update for the second quarter ended June 30, 2013. Synergy is developing plecanatide for the treatment of chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C).

Hey, check out all the engineering jobs. Post your resume today!

Back to news